PGEN News and Press, Precigen Inc. From 05/13/24

2024-05-13 12:16:06 ET More on Precigen Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript J.P. Morgan cuts Precigen to underweight, cites burn rate Seeking Alpha’s Quant Rating on Precigen Historical earnings data for Precigen Financial in...

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting PR Newswire GERMANTOWN, Md. , May 8, 2024 /PRNewswire/ -- Pr...

Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting PR Newswire GERMANTOWN, Md. , April 24, 2024 /...

Actym Therapeutics Appoints Thomas Smart as CEO PR Newswire BERKELEY, Calif. , April 24, 2024 /PRNewswire/ -- Actym Therapeutics , pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Off...

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th PR Newswire – Inaugural multi-stakeholder event on June 11th (6/11)  will raise awareness and bring together individuals living with RRP,...

2024-03-22 11:10:58 ET More on Precigen Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript Precigen: RRP Targeting With AdenoVerse Technology Platform Precigen gets EU orphan drug status for respiratory tract drug Seeking Alpha’s Quant Rating on Pr...

2024-03-19 20:49:04 ET Precigen, Inc. (PGEN) Q4 2023 Earnings Conference Call March 19, 2024 04:30 PM ET Company Participants Steve Harasym - Vice President, Investor Relations Helen Sabzevari - President & Chief Executive Officer Harry Thomasian - Chief Fina...

2024-03-19 16:09:55 ET More on Precigen Precigen: RRP Targeting With AdenoVerse Technology Platform Precigen gets EU orphan drug status for respiratory tract drug Seeking Alpha’s Quant Rating on Precigen Historical earnings data for Precigen Fi...

Precigen Reports Full Year 2023 Financial Results and Business Updates PR Newswire – Significant progress made in the development of the PRGN-2012 AdenoVerse immunotherapy for the treatment of RRP; Precigen plans to submit a BLA under an accelerated approval pathway in ...